Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rohto Pharmaceutical Co ( (JP:4527) ) has issued an announcement.
Rohto Pharmaceutical Co., Ltd. has revised its earnings forecast for the fiscal year ending March 31, 2026, reflecting an increase in ordinary income and profit attributable to owners due to dividend income recorded in the first quarter. The revised forecast indicates a 6.2% increase in ordinary income and a 1.3% increase in profit attributable to owners compared to the previous forecast, with exchange rates remaining stable.
The most recent analyst rating on (JP:4527) stock is a Buy with a Yen4770.00 price target. To see the full list of analyst forecasts on Rohto Pharmaceutical Co stock, see the JP:4527 Stock Forecast page.
More about Rohto Pharmaceutical Co
Rohto Pharmaceutical Co., Ltd. is a company operating in the pharmaceutical industry, primarily focusing on the production and distribution of health-related products. The company is listed on the Tokyo Stock Exchange and is known for its wide range of skincare, healthcare, and pharmaceutical products.
Average Trading Volume: 1,256,832
Technical Sentiment Signal: Sell
Current Market Cap: Yen506.1B
For detailed information about 4527 stock, go to TipRanks’ Stock Analysis page.